PL3386991T3 - Związki wielopierścieniowe jako inhibitory kinazy tyrozynowej brutona - Google Patents

Związki wielopierścieniowe jako inhibitory kinazy tyrozynowej brutona

Info

Publication number
PL3386991T3
PL3386991T3 PL16820106T PL16820106T PL3386991T3 PL 3386991 T3 PL3386991 T3 PL 3386991T3 PL 16820106 T PL16820106 T PL 16820106T PL 16820106 T PL16820106 T PL 16820106T PL 3386991 T3 PL3386991 T3 PL 3386991T3
Authority
PL
Poland
Prior art keywords
bruton
inhibitors
tyrosine kinase
polycyclic compounds
polycyclic
Prior art date
Application number
PL16820106T
Other languages
English (en)
Inventor
Nidhi Arora
Genesis M. Bacani
Joseph Kent Barbay
Scott D. Bembenek
Min Cai
Wei Chen
Charlotte Pooley DECKHUT
James P. Edwards
Brahmananda GHOSH
Kevin Kreutter
Gang Li
Mark S. Tichenor
Jennifer D. Venable
Jianmei Wei
John J. M. Wiener
Yao Wu
Kun Xiao
Feihuang ZHANG
Yaoping Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3386991T3 publication Critical patent/PL3386991T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16820106T 2015-12-10 2016-12-09 Związki wielopierścieniowe jako inhibitory kinazy tyrozynowej brutona PL3386991T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
EP16820106.9A EP3386991B1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase
PCT/US2016/065954 WO2017100662A1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
PL3386991T3 true PL3386991T3 (pl) 2021-03-08

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16820106T PL3386991T3 (pl) 2015-12-10 2016-12-09 Związki wielopierścieniowe jako inhibitory kinazy tyrozynowej brutona

Country Status (29)

Country Link
US (4) US10717745B2 (pl)
EP (2) EP3386991B1 (pl)
JP (2) JP6835846B2 (pl)
KR (1) KR102103395B1 (pl)
CN (2) CN113121562B (pl)
AR (1) AR107042A1 (pl)
AU (1) AU2016366541B2 (pl)
BR (1) BR112018011526B1 (pl)
CA (1) CA3007990C (pl)
CY (1) CY1123263T1 (pl)
DK (1) DK3386991T3 (pl)
EA (1) EA035168B1 (pl)
ES (1) ES2805835T3 (pl)
HR (1) HRP20201193T1 (pl)
HU (1) HUE049502T2 (pl)
IL (1) IL259863B (pl)
JO (1) JO3794B1 (pl)
LT (1) LT3386991T (pl)
MA (2) MA53110A (pl)
MD (1) MD3386991T2 (pl)
ME (1) ME03803B (pl)
MX (1) MX2018007075A (pl)
PL (1) PL3386991T3 (pl)
PT (1) PT3386991T (pl)
RS (1) RS60604B1 (pl)
SI (1) SI3386991T1 (pl)
TW (1) TWI729047B (pl)
UY (1) UY37015A (pl)
WO (1) WO2017100662A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
KR20240019214A (ko) 2021-06-04 2024-02-14 얀센 파마슈티카 엔브이 브루톤 티로신 키나제의 억제제 및 이의 사용 방법
CN117642168A (zh) 2021-06-30 2024-03-01 詹森药业有限公司 布鲁顿酪氨酸激酶的抑制剂及其使用方法
CA3227033A1 (en) 2021-08-09 2023-02-16 Eric Frederik ELDERING Compositions for use in treating b-cell malignancies
WO2023156599A1 (en) * 2022-02-18 2023-08-24 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
JP5305905B2 (ja) 2005-08-08 2013-10-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリミジンキナーゼ阻害剤
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
JP5739334B2 (ja) * 2009-08-26 2015-06-24 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
KR102311329B1 (ko) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
SI3080103T1 (sl) * 2013-12-11 2018-11-30 Biogen Ma Inc. Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
US10934310B2 (en) 2021-03-02
CA3007990A1 (en) 2017-06-15
PT3386991T (pt) 2020-08-18
JP2018536686A (ja) 2018-12-13
MX2018007075A (es) 2018-11-09
AR107042A1 (es) 2018-03-14
HRP20201193T1 (hr) 2020-11-13
UY37015A (es) 2017-06-30
JP6835846B2 (ja) 2021-02-24
AU2016366541B2 (en) 2021-05-13
CN113121562B (zh) 2022-09-13
IL259863B (en) 2020-06-30
BR112018011526B1 (pt) 2024-02-27
AU2016366541A1 (en) 2018-05-31
JO3794B1 (ar) 2021-01-31
EA035168B1 (ru) 2020-05-08
KR102103395B1 (ko) 2020-04-23
MA53110A (fr) 2021-05-12
US20210101910A1 (en) 2021-04-08
WO2017100662A1 (en) 2017-06-15
MA43409B1 (fr) 2020-10-28
US20230097422A1 (en) 2023-03-30
EP3386991B1 (en) 2020-06-03
EP3386991A1 (en) 2018-10-17
CN108884106A (zh) 2018-11-23
JP2021073286A (ja) 2021-05-13
US11319329B2 (en) 2022-05-03
RS60604B1 (sr) 2020-08-31
TW201734021A (zh) 2017-10-01
ME03803B (me) 2021-04-20
US20170283430A1 (en) 2017-10-05
HUE049502T2 (hu) 2020-09-28
MD3386991T2 (ro) 2020-11-30
LT3386991T (lt) 2020-08-25
EA201891378A1 (ru) 2018-12-28
CY1123263T1 (el) 2021-12-31
BR112018011526A2 (pt) 2018-11-21
KR20180093974A (ko) 2018-08-22
EP3719022A1 (en) 2020-10-07
IL259863A (en) 2018-07-31
NZ742484A (en) 2021-09-24
CA3007990C (en) 2024-01-02
JP7072690B2 (ja) 2022-05-20
SI3386991T1 (sl) 2020-08-31
US10717745B2 (en) 2020-07-21
CN113121562A (zh) 2021-07-16
TWI729047B (zh) 2021-06-01
DK3386991T3 (da) 2020-07-13
US20190276471A1 (en) 2019-09-12
ES2805835T3 (es) 2021-02-15

Similar Documents

Publication Publication Date Title
HK1256857A1 (zh) 多氟化合物作為布魯頓酪氨酸激酶抑制劑
IL255831A (en) Inhibitors of bruton's tyrosine kinase
IL259863B (en) Polycyclic compounds as inhibitors of proton tyrosine kinase
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
IL244492A0 (en) Broton tyrosine kinase inhibitors
IL274716A (en) Synthesis of a proton tyrosine kinase inhibitor
IL253995A0 (en) Pharmaceutical formulations of proton tyrosine kinase inhibitor
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
EP3141546A4 (en) Inhibitor of bruton's tyrosine kinase
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
HK1249736A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的共結晶體
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
EP3159340A4 (en) New bruton's tyrosine kinase inhibitor
HK1258699A1 (zh) 包含酪氨酸蛋白激酶抑制劑的劑型組合物
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
HK1249737A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的溶劑化形式
IL252200B (en) A process for the purification of receptor tyrosine kinase inhibitor axl "r 428"
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors